Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 5/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.46 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954699 | 0.93 | NISCH (0.53) | NISCHTAAR1HTR1BADRA2AADRA2B | |
| SCHEMBL953395 | 0.82 | TAAR1 (0.55) | NISCHTAAR1HTR1BADRA2AADRA2B | |
| SCHEMBL26078623 | 0.76 | NISCH (0.58) | NISCHTAAR1HTR1BADRA2AADRA2B | |
| SCHEMBL954891 | 0.73 | TAAR1 (0.76) | NISCHTAAR1HTR1BADRA2AADRA2B | |
| SCHEMBL4630286 | 0.72 | TAAR1 (0.79) | NISCHTAAR1HTR1BADRA2AADRA2B | |
| SCHEMBL952502 | 0.71 | TAAR1 (0.64) | NISCHTAAR1HTR1BADRA2AADRA2B | |
| SCHEMBL9440518 | 0.71 | NISCH (0.50) | NISCHTAAR1HTR1BADRA2AADRA2B | |
| SCHEMBL3407322 | 0.70 | CTSG (0.48) | LMNAALDH1A1HPGD | |
| Naphazoline SCHEMBL4968660 | 0.68 | TAAR1 (0.74) | NISCHTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL4629856 | 0.68 | TAAR1 (0.60) | NISCHTAAR1HTR1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | OPRM1 648/4885NISCH 162/4885TAAR1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.